![Mizrahi Jacques](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Mizrahi Jacques
Directeur/Membre du Conseil chez
Kymo Therapeutics Ltd.
Profil
Mizrahi Jacques is the founder of Inception IBD, Inc. (founded in 2011).
He is currently the Chairman at LiMM Therapeutics SA, Director & VP-Research & Development at ElsaLys Biotech SAS (since 2014), Director at Kymo Therapeutics Ltd., and Venture Partner at Aravis AG (since 2013).
He has also worked as a Director at Eyevensys SAS. Dr. Jacques holds a doctorate degree from the University of Sherbrooke.
Postes actifs de Mizrahi Jacques
| Sociétés | Poste | Début |
|---|---|---|
Aravis AG
 Aravis AG Investment ManagersFinance Aravis is a hands-on investment partner. They work closely with their portfolio firms while providing capital and access to their international network of professionals. The firm's investment strategy targets early-stage firms active in biopharmaceutical, medical technology and biotechnology sectors in Europe, North America and Asia. They have a particular focus on cross-border deals and in firms operating in immunology, inflammation, oncology and CNS segments. They also invest in renewable energy businesses in Europe where they believe there are substantial growth opportunities. They concentrate on firms in the development phase which employ mature established energy production technologies, namely wind, hydroelectric or photovoltaic cells. Aravis has experience initiating, financing and structuring complex projects. The firm aims to diligently conduct scientific and technical analysis of potential projects prior to capital commitment. They look for firms which display optimal risk/return profiles. They closely monitor the quality of the science and actively continue with hands-on intervention in challenging situations, aiming to create value through deal structuring in parallel with careful entry valuations. | Private Equity Investor | 01/01/2013 |
Kymo Therapeutics Ltd.
 Kymo Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Develops and commercializes therapeutic products | Directeur/Membre du Conseil | 20/11/2020 |
Anciens postes connus de Mizrahi Jacques
| Sociétés | Poste | Fin |
|---|---|---|
| ELSALYS BIOTECH | Directeur Technique/Scientifique/R&D | - |
LiMM Therapeutics SA
 LiMM Therapeutics SA Financial ConglomeratesFinance Functions as an investment holding company | Président | - |
Inception IBD, Inc.
 Inception IBD, Inc. Miscellaneous Commercial ServicesCommercial Services Provides therapeutics services | Fondateur | - |
Eyevensys SAS
 Eyevensys SAS Miscellaneous Commercial ServicesCommercial Services Develops non-viral gene therapy process for the treatment of ocular illnesses | Directeur/Membre du Conseil | - |
Formation de Mizrahi Jacques
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
34
Relations au 1er degré
7
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 7 |
|---|---|
University of Sherbrooke
 University of Sherbrooke Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Aravis AG
Aravis AG Investment ManagersFinance Aravis is a hands-on investment partner. They work closely with their portfolio firms while providing capital and access to their international network of professionals. The firm's investment strategy targets early-stage firms active in biopharmaceutical, medical technology and biotechnology sectors in Europe, North America and Asia. They have a particular focus on cross-border deals and in firms operating in immunology, inflammation, oncology and CNS segments. They also invest in renewable energy businesses in Europe where they believe there are substantial growth opportunities. They concentrate on firms in the development phase which employ mature established energy production technologies, namely wind, hydroelectric or photovoltaic cells. Aravis has experience initiating, financing and structuring complex projects. The firm aims to diligently conduct scientific and technical analysis of potential projects prior to capital commitment. They look for firms which display optimal risk/return profiles. They closely monitor the quality of the science and actively continue with hands-on intervention in challenging situations, aiming to create value through deal structuring in parallel with careful entry valuations. | Finance |
Eyevensys SAS
Eyevensys SAS Miscellaneous Commercial ServicesCommercial Services Develops non-viral gene therapy process for the treatment of ocular illnesses | Commercial Services |
ElsaLys Biotech SAS
 ElsaLys Biotech SAS Pharmaceuticals: MajorHealth Technology Designs, develops and supplies antibodies to modulate the immune system of patients | Health Technology |
Inception IBD, Inc.
Inception IBD, Inc. Miscellaneous Commercial ServicesCommercial Services Provides therapeutics services | Commercial Services |
Kymo Therapeutics Ltd.
Kymo Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Develops and commercializes therapeutic products | Health Technology |
LiMM Therapeutics SA
LiMM Therapeutics SA Financial ConglomeratesFinance Functions as an investment holding company | Finance |
